CEO – Bernhard Hofer
Bernhard Hofer completed his master in finance and controlling at the Management Center Innsbruck in 2007 while working as an investment controller for the city of Innsbruck. In 2008 he took over the responsibility for finance and controlling at Oncotyrol GmbH. At the end of 2009 he was promoted to the his current position as CEO and was significantly involved in developing and executing the further strategic and operational orientation of Oncotyrol GmbH. He succeeded to prepare Oncotyrol GmbH to operate as an independent company after end of public funding in spring 2016.
CSO – Lukas Huber
Lukas Huber studied medicine at the University of Innsbruck, followed by postdoc positions at EMBL (Heidelberg) and University of Geneva. From 1996 to 2002 he led a research group at the I.M.P. in Vienna before he was appointed as professor and head of the Division of Cell Biology and scientific director of the Biocenter of Innsbruck Medical University (Austria). His main research interests is spatiotemporal resolution of signaling mechanisms in cells (academic research) and inhibition/control of signaling (translational research). Lukas Huber led several large-scale research consortia (international, national and regional) and, besides his engagement in Oncotyrol, he is scientific director of the Austrian Drug Screening Institute.